Phio Positive Pathology Results: Final Maximum Dose Cohort for Skin Cancer Trial

Phio Pharmaceuticals (NASDAQ: PHIO) reported pathologic results from the fifth and final dose cohort of its Phase 1b INTASYL PH-762 trial in cutaneous carcinomas on November 3, 2025. In the three patients completing the cohort, one had 100% tumor clearance, one had >90% clearance, and one had >50% clearance, with assessments at approximately 5 weeks after initial injection. To date, 18 patients have completed treatment across five cohorts, including 6 complete responses among 16 cSCC patients. The Safety Monitoring Committee reviewed safety at the maximum dose and found no dose-limiting toxicities; overall the trial reports no clinically relevant treatment-emergent adverse effects and dose escalation reached ~20-fold versus cohort 1. Trial identifier: NCT# 06014086.

https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-announces-positive-pathology-results-final-y61yp6mj30na.html